Journal article
Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
R Scott, R O'Brien, G Fulcher, C Pardy, M D'Emden, D Tse, MR Taskinen, C Ehnholm, A Keech
Diabetes Care | AMER DIABETES ASSOC | Published : 2009
DOI: 10.2337/dc08-1543
Abstract
OBJECTIVE - We explored whether cardiovascular disease (CVD) risk and the effects of fenofibrate differed in subjects with and without metabolic syndrome and according to various features of metabolic syndrome defined by the Adult Treatment Panel III (ATP III) in subjects with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. RESEARCH DESIGN AND METHODS - The prevalence of metabolic syndrome and its features was calculated. Cox proportional models adjusted for age, sex, CVD status, and baseline A1C levels were used to determine the independent contributions of metabolic syndrome features to total CVD event rates and the effects of fenofibrate. RESU..
View full abstractGrants
Funding Acknowledgements
This Study was supported by a grant from Laboratoires Fournier SA, Dijon, France, and by the National Health and Medical Research Council (NHMRC) of Australia and was coordinated independently by the NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia, and overseen by the study management committee.R.O., G.F., M.-R.T., C.E., and A.K. have had the costs of participation in scientific meetings and/or contributions to advisory boards or doing Other research reimbursed by Laboratoires Fournier (now a division of Solvay). A.K. is a listed applicant on a patent application in relation to some other findings related to this research. No other Potential conflicts of interest relevant to this article were reported.